Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

I-Corps Program for A rapid instrument-free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood.

Award Number: R43AI125013
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/23/2017
PERIOD OF PERFORMANCE END DATE: 05/31/2017

Group Awards By:

View Award Description

I-Corps Program for A rapid instrument-free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood. - ¿ DESCRIPTION (provided by applicant): The objective of this proposed SBIR Phase I is to complete the proof-of-principle of a novel blood based biomarker assay for the diagnosis and management of Sepsis, pScreen-Sep(tm). pScreen- Sep(tm) has several unique features. It is fully disposable (single use) and does not requires external electronic equipment (i.e., benchtop or handheld devices), hence it is easy to use and very affordable; it is also a quantitative and sensitive platform, hence it provides an accurate and precise quantification of the level of key sepsis biomarkers, such as procalcitonin (PCT). Current research has shown PCT to be a promising biomarker for indicating early onset of sepsis in at risk patients. Severe sepsis, systemic infection and organ dysfunction or tissue hypoperfusion, affects over a million Americans every year, and the incidence of sepsis is increasing at a drastic rate. Severe sepsis kills 20-50% of patients and is the 10th leading cause of death overall in the US, while patients who survive often experience pain, impaired physical functionality, and overall worse health than the general population during their lifetime. Sepsis and related hospitalization cost over $20 billion annually in the US alone, making it the most expensive condition treated in US hospitals. One of the major challenges associated with effective sepsis treatment is the difficulty in early recognition and diagnosis. Starting antibiotics within one hour following the observation of hypotension was found to significantly decrease mortality from sepsis, yet over 50% of patients do not receive antibiotics from more than six hours following onset of hypotension. One study showed that survival decreased by 7.6% per hour that antimicrobial therapy was delayed in the first six hours following the onset of hypotension. A clear and critical need for a prognostc tool exists for diagnosis and management of sepsis. Our solution enables physicians and first responders to rapidly monitor and diagnose potential sepsis at the Point-of-Care of patients. pScreen-sep(tm) is based on a patent-protected technology developed at Carnegie Mellon University, which has been extensively verified in our laboratory. In this Phase I proposal, we will optimize key elements of our latest prototype and complete a detailed validation study that includes positive and negative controls. A clinical trial to support the FDA premarket approval would then follow in a Phase II effort.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2017	ACCEL DIAGNOSTICS, LLC	5930 STAR LN SUITE C	HOUSTON	TX	77057	HARRIS	USA	Allergy and Infectious Diseases Research	000	1	4/9/2018	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $49,046 )
2017	2017	ACCEL DIAGNOSTICS, LLC	5750 BAUM BLVD # 310	PITTSBURGH	PA	15206	ALLEGHENY	USA	Allergy and Infectious Diseases Research	001	1	5/18/2017	SUPPLEMENT FOR EXPANSION	$8,299
2017	2017	ACCEL DIAGNOSTICS, LLC	5750 BAUM BLVD # 310	PITTSBURGH	PA	15206	ALLEGHENY	USA	Allergy and Infectious Diseases Research	000	1	4/5/2017	SUPPLEMENT FOR EXPANSION	$40,747
														Subtotal = $49,046

Issue Date FY: 2016 ( Subtotal = $145,499 )
2016	2016	ACCEL DIAGNOSTICS LLC	3500 5TH AVENUE	PITTSBURGH	PA	15213	ALLEGHENY	USA	Allergy and Infectious Diseases Research	000	1	6/14/2016	NEW	$145,499
														Subtotal = $145,499

Grand Total All Awards = $194,545

Top

All Categories

About

Search

Reports

Data Submission

Award Information

I-Corps Program for A rapid instrument-free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood.

Award Number: R43AI125013

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/23/2017

PERIOD OF PERFORMANCE END DATE: 05/31/2017

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer